Clinical Trials Browser

Interventional × Carcinoma × sintilimab × Clear all

NCT05913661 2023-06-22

Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Phase 2 Unknown

Gastrointestinal

Carcinoma, Digestive System Neoplasms, Cholangiocarcinoma

NCT03765775 2018-12-06

Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative

Phase 2 Unknown

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms